Does oligometastatic breast cancer (OMBC) deserve a dedicated treatment? Although some authors recommend multidisciplinary management of OMBC with a curative intent, there is no evidence proving this strategy beneficial in the absence of a randomized trial. The existing literature sheds little light on OMBC. Incidence is unknown; data available are either obsolete or biased; there is no consensus on the definition of OMBC and metastatic sites, nor on necessary imaging techniques. However, certain proposals merit consideration. Knowledge of eventual specific OMBC biological characteristics is limited to circulating tumor cell (CTC) counts. Given the data available for other cancers, studies on microRNAs (miRNAs), circulating tumor DNA (ctDNA) and genomic alterations should be developed Finally, safe and effective therapies do exist, but results of randomized trials will not be available for many years. Prospective observational cohort studies need to be implemented.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441842 | PMC |
| http://dx.doi.org/10.1016/j.breast.2021.06.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient Perspectives on the Value of Stereotactic Body Radiotherapy in the Management of Breast Cancer: The PERSPECTIVE Study.
Clin Oncol (R Coll Radiol)
December 2024
Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.
Aims: Oligometastatic disease describes limited metastases amenable to therapy such as stereotactic body radiotherapy (SBRT). This study aims to understand which outcomes are most important to patients when considering SBRT as a treatment option. The insights gained will help inform future patient-directed trial endpoints and provide valuable guidance to clinicians supporting patients through their decision-making process.
View Article and Find Full Text PDFMetastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study.
Clin Exp Metastasis
December 2024
Department of Radiation Oncology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str.3, 24105, Kiel, Germany.
Metastasis-directed therapy (MDT) for oligometastatic breast cancer (≤ 5 metastases) has shown little effect in specific scenarios of randomized trials. Therefore, we aimed to assess outcomes after metastasis-directed stereotactic radiotherapy (SRT) in various clinical scenarios. We conducted an international retrospective cohort study in thirteen centers including breast cancer patients receiving SRT to any metastatic site.
View Article and Find Full Text PDFThe role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting.
Front Oncol
December 2024
Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated a survival benefit in the second-line treatment of patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However, identifying prognostic biomarkers remains a challenge. Thus, we aimed to assess the prognostic value of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) performed before CDK4/6 inhibitors initiation.
View Article and Find Full Text PDFPrimary tumor resection in metastatic breast cancer from an oligometastatic perspective: A systematic review and meta-analysis.
iScience
December 2024
Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning Province 110001, China.
Whether patients with metastatic breast cancer ( MBC) benefit from primary tumor resection (PTR) is controversial, and the efficacy of treatment of primary tumor in patients with oligometastases is uncertain. A comprehensive search was conducted for studies published from January 1, 2008 to January 1, 2024 that compared PTR with no PTR for MBC that quantified the extent of metastasis. Ten studies and 83,559 patients with MBC were included.
View Article and Find Full Text PDFTreatment of metastatic breast cancer by stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS).
Discov Oncol
December 2024
Division of Breast Surgery, Department of General Surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, 610041, China.
Background And Purpose: The role of local ablative radiotherapy (stereotactic body radiotherapy (SBRT)/stereotactic radiosurgery (SRS)) in the management of metastatic breast cancer (mBC) patients remains unclear. This study aimed to assess the efficacy of SBRT/SRS in oligometastatic and oligoprogressive breast cancer patients.
Methods: Totally 80 mBC patients with oligometastatic disease (OMD) and 80 with oligoprogressive disease (OPD) to ≤5 metastatic lesions were retrospectively analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!